

State of California—Health and Human Services Agency Department of Health Care Services



DATE: October 11, 2022

CCS Information Notice: 22-04

TO: All County California Children's Services Program Administrators

SUBJECT: Palivizumab for Immunoprophylaxis of Respiratory Syncytial Virus

Infection during 2022- 2023

BACKGROUND

California Children's Services (CCS) is tracking Respiratory Syncytial Virus (RSV) infection test positivity rates in conjunction with the California Department of Public Health (CDPH), which receives RSV test positivity data from regional sentinel laboratories across California. From these data, CDPH prepares aggregated statewide RSV test positivity reports. These reports, together with those of the National Respiratory and Enteric Virus Surveillance System (NREVSS),¹ indicate a pattern of test positivity rates suggesting a relatively earlier start to the RSV season than in typical years, such as 2019 - 2020.

GUIDANCE FOR CURRENT APPARANTLY ATYPICAL RSV SEASON

CCS Numbered Letter (N.L.) 13-0914² describes program policy regarding authorization of Palivizumab immunoprophylaxis of RSV. For the current apparent RSV season only (2022-2023), more than five doses of Palivizumab may be administered; providers may administer up to a maximum of 6 doses per child, if the child receives the first dose in October. Monthly doses from October through April will provide protection through May.

If you have any questions regarding this I.N., please contact Dr. Joseph Schulman, via e-mail at Joseph.Schulman@dhcs.ca.gov.

Sincerely,

ORIGINAL SIGNED BY

Cortney Maslyn
Division Chief
Integrated Systems of Care Division

CCS I.N. 22-04 Page 2 of 2 October 11, 2022

National Respiratory and Enteric Virus Surveillance System (NREVSS)
 https://www.cdc.gov/surveillance/nrevss/rsv/state.html#CA
 CCS Numbered Letter 13-0914

https://www.dhcs.ca.gov/services/ccs/Documents/ccsnl130914.pdf